NCT01392703View on ClinicalTrials.gov

Pharmacokinetic Study Comparing Blood Levels of Dasatinib in Healthy Participants Who Received the Tablet Formulation With Those Who Received Liquid and Tablet-dispersed Formulations

PHASE1CompletedINTERVENTIONAL
Enrollment

141

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Pharmacokinetic Study in Healthy Participants
Interventions
DRUG

Dasatinib as tablets

2 50-mg tablets plus 240 mL noncarbonated, nonrefrigerated water. Oral, single dose, 1 day

DRUG

Dasatinib as liquid

100 mg administered as 10 mL of liquid drug (10 mg/mL) plus 230 mL noncarbonated, nonrefrigerated water. Oral, single dose, 1 day

DRUG

Dasatinib as dispersed tablets

2 50-mg dispersed tablets in 30 mL of 100% orange juice followed by 15 mL of orange juice plus 195 mL noncarbonated, nonrefrigerated water. Liquid (oral solution), single dose, 1 day.

Trial Locations (1)

78209

Healthcare Discoveries Inc., San Antonio

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT01392703 - Pharmacokinetic Study Comparing Blood Levels of Dasatinib in Healthy Participants Who Received the Tablet Formulation With Those Who Received Liquid and Tablet-dispersed Formulations | Biotech Hunter | Biotech Hunter